LONDON, May 17 (Reuters) - AstraZeneca's drive to
rebuild its portfolio of new medicines received a boost with
positive results for an experimental biotech drug for severe
asthma that the company previously flagged as a potential $2
billion-a-year seller.
Read more
No comments:
Post a Comment